PLX (Protalix BioTherapeutics, Inc. Common Stock) Stock Analysis - Analyst Ratings
Protalix BioTherapeutics, Inc. Common Stock (PLX) is a publicly traded Healthcare sector company. As of May 21, 2026, PLX trades at $1.94 with a market cap of $153.89M and a P/E ratio of 10.07. PLX moved +5.53% today. Year to date, PLX is +12.29%; over the trailing twelve months it is +16.86%. Its 52-week range spans $0.99 to $3.19. Analyst consensus is buy with an average price target of $12.00. Rallies surfaces PLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What do analysts rate PLX?
1 analysts cover PLX: 0 strong buy, 1 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $12.00.